Richard J. Ablin

Corporate Officer/Principal en Tetragenex Pharmaceuticals, Inc. .

Consumer Services

Health Technology

Perfil

Richard J.
Ablin is currently the Director of Tetracycline Evaluation at Tetragenex Pharmaceuticals, Inc. He was previously the Director and Research Associate Professor at The State University of New York from 1983 to 1989.
Ablin received his doctorate degree from the State University of New York at Buffalo in 1967.

Cargos activos de Richard J. Ablin

Empresas	Cargo	Inicio
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Corporate Officer/Principal	05/02/2010

Todos los cargos activos de Richard J. Ablin

Antiguos cargos conocidos de Richard J. Ablin.

Empresas	Cargo	Fin
The State University of New York	Director/Miembro de la Junta	01/01/1989

Ver el detalle de la experiencia de Richard J. Ablin.

Formación de Richard J. Ablin.

State University of New York at Buffalo

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Richard J. Ablin.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Health Technology